Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients

Lignende værker

• Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
  af: Jamroz-Wiśniewska, Anna, et al.
  Udgivet: (2021)
• Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases
  af: Anetta, Lasek-Bal, et al.
  Udgivet: (2013)
• Patent foramen ovale and cryptogenic stroke – a statistical or cause-and-effect relationship? A neurological point of view
  af: Lasek-Bal, Anetta, et al.
  Udgivet: (2013)
• Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
  af: Vollmer, Brandi L., et al.
  Udgivet: (2018)
• Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study
  af: Meca-Lallana, José, et al.
  Udgivet: (2020)